JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Organon & Co

Aperta

SettoreSettore sanitario

6.5 0.62

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

6.41

Massimo

6.83

Metriche Chiave

By Trading Economics

Entrata

-174M

-87M

Vendite

81M

1.6B

P/E

Media del settore

3.435

37.461

EPS

1

Rendimento da dividendi

9.27

Margine di Profitto

-5.443

Dipendenti

10,000

EBITDA

124M

449M

Raccomandazioni

By TipRanks

Raccomandazioni

Vendi

Previsioni per 12 mesi

+36.97% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

9.27%

2.33%

Utili prossimi

30 ott 2025

Prossima data del Dividendo

11 dic 2025

Prossima data del' Ex Dividendo

12 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-101M

2.4B

Apertura precedente

5.88

Chiusura precedente

6.5

Notizie sul Sentiment di mercato

By Acuity

42%

58%

131 / 373 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Organon & Co Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 ott 2025, 23:50 UTC

Azioni calde

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 ott 2025, 23:25 UTC

Utili

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 ott 2025, 23:18 UTC

Utili

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 ott 2025, 22:20 UTC

Utili

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 ott 2025, 22:13 UTC

Utili

Wal-Mart de Mexico Net Profit Falls in 3Q

28 ott 2025, 21:38 UTC

Utili

Correction to Visa Sales Jump Article

28 ott 2025, 21:17 UTC

Utili

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 ott 2025, 21:07 UTC

Utili

Visa Sales Jump as Consumers Keep Spending -- Update

28 ott 2025, 21:02 UTC

Utili

Mondelez Tempers Outlook as Costs Rise

28 ott 2025, 23:51 UTC

Discorsi di Mercato

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 ott 2025, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 ott 2025, 23:02 UTC

Utili

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 ott 2025, 23:01 UTC

Utili

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 ott 2025, 22:46 UTC

Utili

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 ott 2025, 22:45 UTC

Utili

SK Hynix 3Q Net KRW12.6T >000660.SE

28 ott 2025, 22:44 UTC

Utili

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 ott 2025, 22:43 UTC

Utili

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 ott 2025, 22:42 UTC

Utili

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 ott 2025, 22:40 UTC

Utili

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 ott 2025, 22:40 UTC

Utili

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 ott 2025, 22:20 UTC

Utili

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 ott 2025, 22:02 UTC

Utili

Review & Preview: Earnings Extravaganza -- Barrons.com

28 ott 2025, 21:42 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

28 ott 2025, 21:42 UTC

Discorsi di Mercato
Utili

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 ott 2025, 21:20 UTC

Utili

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 ott 2025, 21:19 UTC

Utili

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 ott 2025, 21:18 UTC

Utili

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Confronto tra pari

Modifica del prezzo

Organon & Co Previsione

Obiettivo di Prezzo

By TipRanks

36.97% in crescita

Previsioni per 12 mesi

Media 9.67 USD  36.97%

Alto 14 USD

Basso 5 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Organon & Co - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Vendi

3 ratings

0

Acquista

1

Mantieni

2

Vendi

Punteggio Tecnico

By Trading Central

8.53 / 9.18Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

131 / 373 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
help-icon Live chat